Sign In

Login

Password

Forgot Password ? Sign Up

Raltégravir (French Wikipedia)

Analysis of information sources in references of the Wikipedia article "Raltégravir" in French language version.

refsWebsite
Global rank French rank
11nih.gov
4th place
12th place
5aidsmeds.com
low place
low place
3europa.eu
68th place
67th place
3issn.org
57th place
4th place
3doi.org
2nd place
3rd place
2actions-traitements.org
low place
low place
2vih.org
low place
low place
1qmul.ac.uk
1,735th place
168th place
1arcat-sante.org
low place
low place
1medscape.com
719th place
1,716th place
1asm.org
3,555th place
1,209th place
1seronet.info
low place
low place
1doctissimo.fr
low place
785th place
1groupesida.ch
low place
low place
1edimark.fr
low place
3,343rd place
1catie.ca
low place
low place
1hivandhepatitis.com
low place
low place

actions-traitements.org

aidsmeds.com

arcat-sante.org

asm.org

aac.asm.org

catie.ca

doctissimo.fr

doi.org

dx.doi.org

  • Nathalie De Castro, Joséphine Braun, Isabelle Charreau et Gilles Pialoux, « Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial », Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, vol. 49, no 8,‎ , p. 1259–1267 (ISSN 1537-6591, PMID 19757993, DOI 10.1086/605674, lire en ligne, consulté le )
  • Constance Delaugerre, Isabelle Charreau, Josephine Braun et Marie-Laure Néré, « Time course of total HIV-1 DNA and 2-long-terminal repeat circles in patients with controlled plasma viremia switching to a raltegravir-containing regimen », AIDS (London, England), vol. 24, no 15,‎ , p. 2391–2395 (ISSN 1473-5571, PMID 20683319, DOI 10.1097/QAD.0b013e32833d214c, lire en ligne, consulté le )
  • Thomas Boulet, Juliette Pavie, Isabelle Charreau et Joséphine Braun, « Impact on health-related quality of life of a switch from enfuvirtide to raltegravir among multidrug-resistant HIV-1-infected patients: a randomized open-label trial (EASIER-ANRS 138) », HIV clinical trials, vol. 11, no 5,‎ , p. 283–293 (ISSN 1528-4336, PMID 21126958, DOI 10.1310/hct1105-283, lire en ligne, consulté le )

edimark.fr

europa.eu

emea.europa.eu

groupesida.ch

hivandhepatitis.com

issn.org

portal.issn.org

  • Nathalie De Castro, Joséphine Braun, Isabelle Charreau et Gilles Pialoux, « Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial », Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, vol. 49, no 8,‎ , p. 1259–1267 (ISSN 1537-6591, PMID 19757993, DOI 10.1086/605674, lire en ligne, consulté le )
  • Constance Delaugerre, Isabelle Charreau, Josephine Braun et Marie-Laure Néré, « Time course of total HIV-1 DNA and 2-long-terminal repeat circles in patients with controlled plasma viremia switching to a raltegravir-containing regimen », AIDS (London, England), vol. 24, no 15,‎ , p. 2391–2395 (ISSN 1473-5571, PMID 20683319, DOI 10.1097/QAD.0b013e32833d214c, lire en ligne, consulté le )
  • Thomas Boulet, Juliette Pavie, Isabelle Charreau et Joséphine Braun, « Impact on health-related quality of life of a switch from enfuvirtide to raltegravir among multidrug-resistant HIV-1-infected patients: a randomized open-label trial (EASIER-ANRS 138) », HIV clinical trials, vol. 11, no 5,‎ , p. 283–293 (ISSN 1528-4336, PMID 21126958, DOI 10.1310/hct1105-283, lire en ligne, consulté le )

medscape.com

nih.gov

ncbi.nlm.nih.gov

  • Nathalie De Castro, Joséphine Braun, Isabelle Charreau et Gilles Pialoux, « Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial », Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, vol. 49, no 8,‎ , p. 1259–1267 (ISSN 1537-6591, PMID 19757993, DOI 10.1086/605674, lire en ligne, consulté le )
  • Constance Delaugerre, Isabelle Charreau, Josephine Braun et Marie-Laure Néré, « Time course of total HIV-1 DNA and 2-long-terminal repeat circles in patients with controlled plasma viremia switching to a raltegravir-containing regimen », AIDS (London, England), vol. 24, no 15,‎ , p. 2391–2395 (ISSN 1473-5571, PMID 20683319, DOI 10.1097/QAD.0b013e32833d214c, lire en ligne, consulté le )
  • Thomas Boulet, Juliette Pavie, Isabelle Charreau et Joséphine Braun, « Impact on health-related quality of life of a switch from enfuvirtide to raltegravir among multidrug-resistant HIV-1-infected patients: a randomized open-label trial (EASIER-ANRS 138) », HIV clinical trials, vol. 11, no 5,‎ , p. 283–293 (ISSN 1528-4336, PMID 21126958, DOI 10.1310/hct1105-283, lire en ligne, consulté le )
  • Deeks SG, Tracy R, Douek DC.. Systemic effects of inflammation on health during chronic HIV infection. Immunity 2013; 39:633-45; PMID 24138880; https://dx.doi.org/10.1016/j.immuni.2013.10.001 [PMC free article] [PubMed] [CrossRef]
  • Sandler NG, Wand H, Roque A, Law M, Nason MC, Nixon DE, Pedersen C, Ruxrungtham K, Lewin SR, Emery S, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 2011; 203:780-90; PMID 21252259; https://dx.doi.org/10.1093/infdis/jiq118 [PMC free article][PubMed] [CrossRef]
  • Tenorio AR, Zheng Y, Bosch RJ, Krishnan S, Rodriguez B, Hunt PW, Plants J, Seth A, Wilson CC, Deeks SG, et al. Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. J Infect Dis 2014; 210:1248-59; PMID 24795473; https://dx.doi.org/10.1093/infdis/jiu254 [PMC free article] [PubMed] [CrossRef]
  • Hunt PW, Sinclair E, Rodriguez B, Shive C, Clagett B, Funderburg N, Robinson J, Huang Y, Epling L, Martin JN, et al. Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection. J Infect Dis 2014; 210:1228-38; PMID 24755434; https://dx.doi.org/10.1093/infdis/jiu238 [PMC free article] [PubMed] [CrossRef]
  • Serrano-Villar S, Sainz T, Ma ZM, Utay NS, Chun TW, Mann S, Kashuba AD, Siewe B, Albanese A, Troia-Cancio P, et al. Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naive to Antiretroviral Therapy: A Pilot Randomized Trial. PLoS Pathog 2016; 12:e1005540; PMID 27015639; https://dx.doi.org/10.1371/journal.ppat.1005540 [PMC free article] [PubMed] [CrossRef]

pubmed.ncbi.nlm.nih.gov

  • Nathalie De Castro, Joséphine Braun, Isabelle Charreau et Gilles Pialoux, « Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial », Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, vol. 49, no 8,‎ , p. 1259–1267 (ISSN 1537-6591, PMID 19757993, DOI 10.1086/605674, lire en ligne, consulté le )
  • Constance Delaugerre, Isabelle Charreau, Josephine Braun et Marie-Laure Néré, « Time course of total HIV-1 DNA and 2-long-terminal repeat circles in patients with controlled plasma viremia switching to a raltegravir-containing regimen », AIDS (London, England), vol. 24, no 15,‎ , p. 2391–2395 (ISSN 1473-5571, PMID 20683319, DOI 10.1097/QAD.0b013e32833d214c, lire en ligne, consulté le )
  • Thomas Boulet, Juliette Pavie, Isabelle Charreau et Joséphine Braun, « Impact on health-related quality of life of a switch from enfuvirtide to raltegravir among multidrug-resistant HIV-1-infected patients: a randomized open-label trial (EASIER-ANRS 138) », HIV clinical trials, vol. 11, no 5,‎ , p. 283–293 (ISSN 1528-4336, PMID 21126958, DOI 10.1310/hct1105-283, lire en ligne, consulté le )

qmul.ac.uk

chem.qmul.ac.uk

seronet.info

vih.org